Intellia Therapeutics, Inc. ($NTLA) Stock Forecast: Down 7.9% Today

What is Intellia Therapeutics, Inc.?

Intellia Therapeutics (NTLA) is a clinical-stage biopharmaceutical firm specializing in CRISPR gene editing for severe diseases. The stock experienced significant downward movement recently.

Why is Intellia Therapeutics, Inc. going down?

NTLA stock is down 7.9% on Mar 11, 2026 13:43

• Despite promising long-term data for its HAE candidate and FDA approval for its ATTR-CM therapy, concerns persist among investors regarding ongoing losses, liver safety issues, and lengthy path to profitability.
• The participation in the Leerink Global Healthcare Conference could give the company a chance to address investor worries and clarify its strategic outlook.
• The stock price surge following the FDA's removal of clinical holds on its gene-editing drug nex-z reflects investor confidence, although safety concerns and high costs of gene-editing therapies remain.
• NTLA is deemed undervalued compared to its fair value estimate, indicating that investors, despite recent positive developments, are still wary of potential clinical hurdles or slow therapy adoption that could impact future performance.

NTLA Price Chart

NTLA Technical Analysis

NTLA News

Is Intellia Therapeutics (NTLA) Turning Regulatory Scrutiny Into a Strategic Edge in Gene Editing?

Intellia Therapeutics has reported positive long-term data for its HAE candidate and regained FDA clearance for its ATTR-CM therapy, highlighting its effort to establish gene-editing treatments as alternatives to chronic therapies. These developments reinforce the company's investment narrative focused on the commercial viability of in vivo CRISPR, shifting investor attention from regulatory uncertainty to execution risk in late-stage trials. Despite recent progress and a recovering share price, investors need to consider ongoing losses, tight liver safety scrutiny, and long timelines to profitability.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ntla/intellia-therapeutics/news/is-intellia-therapeutics-ntla-turning-regulatory-scrutiny-in

Leerink Global Healthcare Conference - Intellia Therapeutics

Intellia Therapeutics is scheduled to participate in the Leerink Global Healthcare Conference on March 9, 2026, at 8:40 AM EDT in Miami, FL. The event will include a webcast, and details are available on the company's investor relations page.

https://ir.intelliatx.com/events/event-details/leerink-global-healthcare-conference

Assessing Intellia Therapeutics (NTLA) Valuation After FDA Hold Lift And New Gene Editing Data

Intellia Therapeutics has seen its stock performance improve significantly following the FDA lifting a clinical hold on its MAGNITUDE Phase 3 trial and promising new data for its hereditary angioedema gene editing therapy, lonvoguran ziclumeran. Despite recent gains, analysis suggests NTLA is currently undervalued, with a fair value estimate of $23.86 compared to its current trading price of $13.44, predicated on strong long-term growth and market expansion assumptions. Investors are encouraged to review the underlying financial data and potential risks, such as clinical setbacks or slower therapy adoption, which could impact future performance.

https://www.sahmcapital.com/news/content/assessing-intellia-therapeutics-ntla-valuation-after-fda-hold-lift-and-new-gene-editing-data-2026-03-07

Cathie Wood's Intellia Therapeutics Surges 47%: Is It Too Late to Invest?

Intellia Therapeutics has seen a 47% surge in its stock price this year, driven by the FDA lifting clinical holds on its gene-editing drug nex-z for hereditary angioedema. While this development has boosted investor confidence and offers potential new revenue streams, the company still faces risks related to unclarified safety concerns and the high costs and complexities of gene-editing therapies. Analysts have mixed views, with some upgrading the stock due to regulatory clarity, while others maintain a neutral stance despite increased price targets.

https://intellectia.ai/news/stock/cathie-woods-intellia-therapeutics-surges-47-is-it-too-late-to-invest

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Intellia Therapeutics, Inc. announced inducement grants to six new employees on March 1, 2026, consisting of 16,500 restricted stock units (RSUs) vesting over three years. These grants were made under Intellia's 2024 Inducement Plan as a material inducement for employment, in compliance with Nasdaq Listing Rule 5635(c)(4). The company is a clinical-stage biopharmaceutical firm focused on CRISPR gene editing to treat severe diseases.

https://www.globenewswire.com/news-release/2026/03/06/3251301/0/en/intellia-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4.html

Trending Today

FuelCell Energy ($FCEL) Stock Forecast: Down 5.0% Today

Plug Power Inc. ($PLUG) Stock Forecast: Down 5.1% Today

DENTSPLY SIRONA Inc. ($XRAY) Stock Forecast: Down 6.0% Today

Ulta Beauty Inc. ($ULTA) Stock Forecast: Down 14.0% Today

SNDL Inc. ($SNDL) Stock Forecast: Down 5.6% Today

Amplitude Inc. ($AMPL) Stock Forecast: Down 5.3% Today

Freeport-McMoRan Inc. ($FCX) Stock Forecast: Down 5.3% Today

Intuitive Surgical Inc. ($ISRG) Stock Forecast: Down 4.7% Today

Capri Holdings Limited ($CPRI) Stock Forecast: Up 5.3% Today

Lemonda Inc. ($LMND) Stock Forecast: Up 5.2% Today

Intellia Therapeutics, Inc. Price History

26.01.2026 - NTLA Stock was up 10.7%

• After revealing its Q4 earnings, NTLA stock saw a noteworthy increase in value, surprising analysts who had forecast a marginal decrease in both EPS and revenue compared to the previous year.
• The FDA's decision to remove a clinical hold on Intellia's gene-editing medication had a favorable impact on the stock's performance, hinting at potential competitiveness in the rare disease pharmaceuticals market.
• Intellia's upcoming involvement in investor conferences scheduled for March 2026 also played a role in boosting market confidence, as investors displayed keen interest in the company's strategic vision and growth prospects.

13.01.2026 - NTLA Stock was up 8.7%

• The FDA's decision to lift the clinical hold on Intellia Therapeutics' MAGNITUDE-2 Phase 3 trial for nexiguran ziclumeran was a significant positive driver for the stock, leading to a notable increase in share price.
• Despite this positive development, concerns about the company's profitability and high price-to-sales ratio relative to industry averages have sparked discussions about the stock's valuation and future growth prospects.
• Analysts, on average, recommend holding the stock with a price target of $18.00. Insider selling and institutional ownership changes contribute to the mixed outlook on NTLA's valuation and potential future performance.

05.02.2026 - NTLA Stock was down 5.1%

• The bearish movement in NTLA stock today could be attributed to profit-taking by investors after a recent surge in the stock price.
• Actions impacting GLP-1 compounders by the FDA might have raised concerns about regulatory scrutiny in the biotech sector, negatively affecting NTLA's stock.
• Despite positive clinical news and increased stake by Vanguard Group Inc., the overall market sentiment towards biotech companies like Intellia might have been affected by the uncertainty surrounding FDA actions and regulatory compliance.
• Insider sales at Intellia, the company's pre-revenue status, and negative margins could have also contributed to the bearish sentiment among investors.

05.02.2026 - NTLA Stock was down 5.1%

• Despite recent positive developments, such as analyst upgrades, strong financial results, and progress with its Phase 3 trial after regulatory hurdles were resolved, Intellia Therapeutics saw a decline in its stock price.
• The market response may have been influenced by the company's decision to expand its At-The-Market offering program to $1.04 billion, which could potentially lead to dilution of existing shares and impact shareholder value.
• Concerns regarding the company's financial performance, such as negative margins and a high valuation, despite advancements in its pipeline and clinical work, might have unsettled investors.
• The divergence in opinions among analysts and the uncertainty surrounding Intellia's path to profitability likely contributed to the negative market sentiment, even amidst positive strides in its therapeutic initiatives.

03.02.2026 - NTLA Stock was down 5.1%

• The stock price of Intellia Therapeutics plummeted despite recent positive developments and analyst upgrades, indicating a possible case of "buy the rumor, sell the news" behavior among investors.
• The FDA's decision to lift the clinical hold on the MAGNITUDE Phase 3 trial for a key therapy was initially seen as a positive development, but concerns over the safety and efficacy of the treatment may have led to the market's negative reaction.
• The company's decision to increase its At-The-Market offering program to $1.04 billion could have also contributed to the bearish sentiment, signaling potential dilution of existing shares and impacting shareholder value.
• Overall, the market movement suggests that investors may be exercising caution and reevaluating their positions in Intellia Therapeutics amidst a mix of positive news and financial decisions by the company.

24.01.2026 - NTLA Stock was up 5.7%

• The development of an investigational gene editing therapy for hereditary transthyretin (ATTR) amyloidosis through CRISPR/Cas9 technology has likely spurred investor optimism and interest in Intellia Therapeutics.
• Encouraging reduction in harmful protein production observed in early clinical trial findings could pave the way for advancements in treating genetic disorders, potentially enhancing the company's standing and stock performance.
• Noteworthy institutional investments, such as those from Jupiter Asset Management Ltd. amounting to $23.52 million, signal increasing confidence in Intellia Therapeutics' future prospects and may have influenced the recent positive market trend.
• Anticipation surrounding an imminent conference call to discuss financial results and business updates could be fueling positive investor sentiment and driving up the stock price.

19.01.2026 - NTLA Stock was up 6.3%

• The bullish movement in NTLA stock today is linked to the lifting of the clinical hold on the MAGNITUDE-2 study, enabling expanded enrollment and updated safety protocols.
• The scheduled conference call to discuss fourth-quarter and full-year 2025 financial results and business updates likely impacted investor confidence in the company's future.
• H.C. Wainwright's increased price target and reiterated Buy rating contributed to a positive investor sentiment towards Intellia Therapeutics.
• Investor optimism about Intellia's gene-editing platform has been bolstered by regulatory clearance and the company's safety improvement efforts, driving the bullish market movement.

10.01.2026 - NTLA Stock was down 5.2%

• Despite recent developments in its MAGNITUDE-2 Phase 3 trial, Intellia Therapeutics (NTLA) saw a 6.6% decline in its stock price.
• Concerns over the ongoing hold on another trial, ATTR-CM MAGNITUDE, have affected investor confidence and contributed to the stock's bearish movement.
• Analysts' decision to maintain a "Hold" rating, reduce price targets, and insider selling have further impacted the sentiment surrounding NTLA's stock.
• The company's status as currently loss-making, alongside debates on its valuation, has led to increased stock volatility and caution among investors regarding future regulatory challenges.

18.01.2026 - NTLA Stock was up 5.1%

• The surge in NTLA stock can be linked to the regulatory approval to resume the MAGNITUDE-2 study with expanded enrollment and enhanced safety protocols.
• Analysts, including H.C. Wainwright, have raised price targets and reiterated Buy ratings on NTLA, showing increased confidence in the company's gene-editing technology.
• Investors are focusing on the trial progress, safety updates, and Intellia's path to profitability amid industry competition despite regulatory advancements.
• The decision to lift the clinical hold marks a significant milestone for Intellia, potentially altering its risk profile and impacting future pricing discussions and partnership opportunities.

27.01.2026 - NTLA Stock was up 5.2%

• Intellia Therapeutics (NTLA) reported a Q4 loss of $0.83 per share, but exceeded revenue estimates, indicating strong potential for revenue growth.
• The positive momentum was driven by an earnings beat, promising trial data for hereditary angioedema, and the release of an FDA clinical hold, boosting investor confidence in the company's pipeline.
• The stock's valuation narrative is mixed, with discussions about high current multiples but substantial undervaluation based on future revenue potential, emphasizing the significance of upcoming milestones such as the Phase 3 HAELO trial for future growth.
• Despite recent share price increases, the company's three-year return is negative, signaling investor optimism about Intellia Therapeutics' long-term prospects despite some short-term obstacles.

02.02.2026 - NTLA Stock was up 5.6%

• Intellia Therapeutics observed a significant uptrend in trading today, driven by a variety of positive developments:
• The company posted strong Q4 2025 earnings and revenue, surpassing expectations and demonstrating robust financial performance.
• Analysts at Chardan Capital reiterated a "Buy" rating with a target price of $26, showcasing confidence in the company's growth trajectory.
• Investor optimism has been fueled by Intellia's focus on its lonvo-z candidate for HAE, with upcoming Phase 3 data and a BLA submission.
• The FDA's removal of the clinical hold on Intellia's MAGNITUDE-2 trial for its gene-editing programs has further bolstered positive sentiment surrounding the stock.

11.02.2026 - NTLA Stock was down 7.9%

• Despite promising long-term data for its HAE candidate and FDA approval for its ATTR-CM therapy, concerns persist among investors regarding ongoing losses, liver safety issues, and lengthy path to profitability.
• The participation in the Leerink Global Healthcare Conference could give the company a chance to address investor worries and clarify its strategic outlook.
• The stock price surge following the FDA's removal of clinical holds on its gene-editing drug nex-z reflects investor confidence, although safety concerns and high costs of gene-editing therapies remain.
• NTLA is deemed undervalued compared to its fair value estimate, indicating that investors, despite recent positive developments, are still wary of potential clinical hurdles or slow therapy adoption that could impact future performance.